159 related articles for article (PubMed ID: 33824480)
1. Sequential targeting of PI3Kδ and LAG3 as an effective anti-cancer approach.
Lauder SN; Vanhaesebroeck B; Gallimore A
Br J Cancer; 2021 Aug; 125(4):467-469. PubMed ID: 33824480
[TBL] [Abstract][Full Text] [Related]
2. Enhanced antitumor immunity through sequential targeting of PI3Kδ and LAG3.
Lauder SN; Smart K; Kersemans V; Allen D; Scott J; Pires A; Milutinovic S; Somerville M; Smart S; Kinchesh P; Lopez-Guadamillas E; Hughes E; Jones E; Scurr M; Godkin A; Friedman LS; Vanhaesebroeck B; Gallimore A
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33093155
[TBL] [Abstract][Full Text] [Related]
3. PI3Kγδ inhibitor plus radiation enhances the antitumour immune effect of PD-1 blockade in syngenic murine breast cancer and humanised patient-derived xenograft model.
Han MG; Jang BS; Kang MH; Na D; Kim IA
Eur J Cancer; 2021 Nov; 157():450-463. PubMed ID: 34601286
[TBL] [Abstract][Full Text] [Related]
4. Shed it, and help-LAG3 cleavage drives conventional CD4
Seidel L; Bengsch B
Sci Immunol; 2020 Jul; 5(49):. PubMed ID: 32680953
[TBL] [Abstract][Full Text] [Related]
5. Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding.
Andrews LP; Somasundaram A; Moskovitz JM; Szymczak-Workman AL; Liu C; Cillo AR; Lin H; Normolle DP; Moynihan KD; Taniuchi I; Irvine DJ; Kirkwood JM; Lipson EJ; Ferris RL; Bruno TC; Workman CJ; Vignali DAA
Sci Immunol; 2020 Jul; 5(49):. PubMed ID: 32680952
[TBL] [Abstract][Full Text] [Related]
6. Research Progress Concerning Dual Blockade of Lymphocyte-Activation Gene 3 and Programmed Death-1/Programmed Death-1 Ligand-1 Blockade in Cancer Immunotherapy: Preclinical and Clinical Evidence of This Potentially More Effective Immunotherapy Strategy.
Qi Y; Chen L; Liu Q; Kong X; Fang Y; Wang J
Front Immunol; 2020; 11():563258. PubMed ID: 33488573
[TBL] [Abstract][Full Text] [Related]
7. LAG3 (CD223) and autoimmunity: Emerging evidence.
Hu S; Liu X; Li T; Li Z; Hu F
J Autoimmun; 2020 Aug; 112():102504. PubMed ID: 32576412
[TBL] [Abstract][Full Text] [Related]
8. Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor.
Ruffo E; Wu RC; Bruno TC; Workman CJ; Vignali DAA
Semin Immunol; 2019 Apr; 42():101305. PubMed ID: 31604537
[TBL] [Abstract][Full Text] [Related]
9. Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance.
Li Y; Liu J; Gao L; Liu Y; Meng F; Li X; Qin FX
Immunol Lett; 2020 Apr; 220():88-96. PubMed ID: 30885690
[TBL] [Abstract][Full Text] [Related]
10. Wnt Inhibition Sensitizes PD-L1 Blockade Therapy by Overcoming Bone Marrow-Derived Myofibroblasts-Mediated Immune Resistance in Tumors.
Huang T; Li F; Cheng X; Wang J; Zhang W; Zhang B; Tang Y; Li Q; Zhou C; Tu S
Front Immunol; 2021; 12():619209. PubMed ID: 33790893
[TBL] [Abstract][Full Text] [Related]
11. Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target.
Qian W; Zhao M; Wang R; Li H
J Hematol Oncol; 2021 Sep; 14(1):147. PubMed ID: 34526102
[TBL] [Abstract][Full Text] [Related]
12. An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitumor immunity and synergizes with PD-1 or LAG-3 blockade.
Zuo S; Wei M; Xu T; Kong L; He B; Wang S; Wang S; Wu J; Dong J; Wei J
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34949694
[TBL] [Abstract][Full Text] [Related]
13. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
[TBL] [Abstract][Full Text] [Related]
14. Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME).
Bretz AC; Parnitzke U; Kronthaler K; Dreker T; Bartz R; Hermann F; Ammendola A; Wulff T; Hamm S
J Immunother Cancer; 2019 Nov; 7(1):294. PubMed ID: 31703604
[TBL] [Abstract][Full Text] [Related]
15. Cooperative Targeting of Immunotherapy-Resistant Melanoma and Lung Cancer by an AXL-Targeting Antibody-Drug Conjugate and Immune Checkpoint Blockade.
Boshuizen J; Pencheva N; Krijgsman O; Altimari DD; Castro PG; de Bruijn B; Ligtenberg MA; Gresnigt-Van den Heuvel E; Vredevoogd DW; Song JY; Visser N; Apriamashvili G; Janmaat ML; Plantinga TS; Franken P; Houtkamp M; Lingnau A; Jure-Kunkel M; Peeper DS
Cancer Res; 2021 Apr; 81(7):1775-1787. PubMed ID: 33531370
[TBL] [Abstract][Full Text] [Related]
16. Intravenous injection of the oncolytic virus M1 awakens antitumor T cells and overcomes resistance to checkpoint blockade.
Liu Y; Cai J; Liu W; Lin Y; Guo L; Liu X; Qin Z; Xu C; Zhang Y; Su X; Deng K; Yan G; Liang J
Cell Death Dis; 2020 Dec; 11(12):1062. PubMed ID: 33311488
[TBL] [Abstract][Full Text] [Related]
17. Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment.
Song Y; Fu Y; Xie Q; Zhu B; Wang J; Zhang B
Front Immunol; 2020; 11():1956. PubMed ID: 32983126
[TBL] [Abstract][Full Text] [Related]
18. LAG3 (CD223) as a cancer immunotherapy target.
Andrews LP; Marciscano AE; Drake CG; Vignali DA
Immunol Rev; 2017 Mar; 276(1):80-96. PubMed ID: 28258692
[TBL] [Abstract][Full Text] [Related]
19. Exosomal PD-L1: Roles in Tumor Progression and Immunotherapy.
Morrissey SM; Yan J
Trends Cancer; 2020 Jul; 6(7):550-558. PubMed ID: 32610067
[TBL] [Abstract][Full Text] [Related]
20. What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy?
Wang Q; Xie B; Liu S; Shi Y; Tao Y; Xiao D; Wang W
Front Immunol; 2021; 12():773168. PubMed ID: 35003090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
